Argenx weakness attributed to Vyvgart Hytrulo inclusion on FDA FAERS update

Shares of Argenx (ARGX) have moved sharply lower in late morning trading and are down $14.12, or 2.5%, to $546.02 as of the time of this alert as traders circulate a posting that outlines drug product(s) with potential signals of serious risks/new safety information by the FDA based on a review of the FAERS system for January to March of this year. Vyvgart Hytrulo is listed as having “severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy” as a potential signas of a serious risks/new safety information and the posting states the FDA is “evaluating the need for regulatory action.”